Antonis V.
- Country
- Sweden
- Department
- Oncology
Research Overview
- Biomarker-Driven Targeted Therapy in Advanced Cancer: A Swedish Nationwide Clinical Trial (FOCU.SE)
- Evaluation of Triptorelin for Ovarian Reserve Preservation in Young Females Undergoing Chemotherapy for Breast Cancer, Leukemia, Lymphomas, and Sarcomas
- Evaluation of Geriatric Assessment-Guided Dose Optimization of CDK 4/6 Inhibitors in Vulnerable Elderly Patients with Advanced Breast Cancer
Data & Insights
Has run more than one trial at 78 of 306 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in multiple aspects of breast cancer treatment, with particular emphasis on hormone receptor-positive and HER2-positive breast cancers. Their research encompasses both early-stage and advanced disease management.
- Neoadjuvant Therapy Innovation
- Endocrine Treatment Optimization
- Advanced/Metastatic Disease Management
The investigator focuses on developing personalized treatment approaches for different breast cancer subtypes.
Geriatric Oncology
Expertise in treating older breast cancer patients, with specific interest in developing optimized treatment protocols that consider age-related factors and vulnerabilities.
- Age-Adapted Dosing Strategies
- Treatment Tolerance Assessment
- Quality of Life Optimization
Their work includes evaluation of treatment modifications for better tolerability in elderly patients.
Melanoma Treatment
The investigator conducts research in advanced melanoma therapeutics, focusing on both early-stage disease prevention and management of unresectable or metastatic melanoma.
- Targeted Therapy Development
- Recurrence Prevention Strategies
- Novel Treatment Combinations
Their research includes investigation of innovative therapeutic approaches for various melanoma stages.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.